A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China

被引:26
作者
Chang, Feng [1 ]
Xi, Yue [1 ]
Zhao, Jie [2 ]
Zhang, Xiaojian [2 ]
Lu, Yun [1 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing 210008, Jiangsu, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou, Henan, Peoples R China
关键词
adverse drug reaction; autoregressive integrated moving average (ARIMA) models; financial incentive; reporting; PHYSICIANS ATTITUDES; PHARMACOVIGILANCE; KNOWLEDGE; DOCTORS;
D O I
10.1111/jep.12780
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rationale, aims, and objectivesSpontaneous reporting of adverse drug reactions (ADRs) in hospitals is often under-reported, which may lead to problems in patient management. This study was aimed to assess the effectiveness of a financial intervention based on a fine and a bonus for improving spontaneous reporting of ADRs by physicians in a hospital setting. MethodsThis study was conducted at the First Affiliated Hospital of Zhengzhou University (China). Starting in 2009, a bonus of 20RMB (Chinese currency) was given for each spontaneous ADR report, and a fine of 50RMB was given for any withheld ADR report. A time series analysis using autoregressive integrated moving average models was performed to assess the changes in the total number of spontaneous ADR reports between the preintervention period (2006-2008) and during the first (2009-2011) and second (2012-2014) intervention periods. ResultsThe median number of reported ADRs per year increased from 29 (range 27-72) in the preintervention period to 277 (range 199-284) in the first intervention period and to 666 in the second (range 644-691). The monthly number of reported ADRs was stable during the 3 periods: 3.563.60/month (95% confidence interval (CI), 2.42-4.75) during the preintervention period, 21 +/- 13/month (95% CI, 16.97-25.80) in the first intervention period, and 56 +/- 20/month (95% CI, 48.81-62.17) in the second intervention period. ConclusionA financial incentive and ADR management regulations had a significant effect on the increase of reported ADRs.
引用
收藏
页码:1316 / 1321
页数:6
相关论文
共 32 条
[1]  
[Anonymous], 1994, Time Series Analysis, Forecasting and Control
[2]  
ARMADANS L, 1988, MED CLIN-BARCELONA, V91, P124
[3]   A small economic inducement to stimulate increased reporting of adverse drug reactions -: a way of dealing with an old problem? [J].
Bäckström, M ;
Mjörndal, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (05) :381-385
[4]   Attitudes to reporting adverse drug reactions in northern Sweden [J].
Bäckström, M ;
Mjörndal, T ;
Dahlqvist, R ;
Nordkvist-Olsson, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) :729-732
[5]   Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union [J].
Belton, KJ ;
Gram, LF ;
Royer, RJ ;
Feely, J ;
McGettigan, P ;
Velo, GP ;
Conforti, A ;
Leone, R ;
Stricker, BHC ;
Teixeira, F ;
Laporte, JP ;
Capella, D ;
Beermann, B ;
Lewis, SC ;
Payne, S ;
Rawlins, MD ;
Wood, SM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (06) :423-427
[6]   A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme [J].
Bracchi, RCG ;
Houghton, J ;
Woods, FJ ;
Thomas, S ;
Smail, SA ;
Routledge, PA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (02) :221-223
[7]  
Capella D, 1993, PRINCIPIOS EPIDEMIOL
[8]   Stimulating adverse drug reaction reporting -: Effect of a drug safety bulletin and of including yellow cards in prescription pads [J].
Castel, JM ;
Figueras, A ;
Pedrós, C ;
Laporte, JR ;
Capellà, D .
DRUG SAFETY, 2003, 26 (14) :1049-1055
[9]   A survey of the knowledge, attitude and practice of adverse drug reaction reporting by clinicians in Eastern India [J].
Chatterjee, Suparna ;
Lyle, Nazmun ;
Ghosh, Souvik .
DRUG SAFETY, 2006, 29 (07) :641-642
[10]  
Cosentino M, 1999, PHARMACOEPIDEM DR S, V8, pS27, DOI 10.1002/(SICI)1099-1557(199904)8:1+<S27::AID-PDS407>3.3.CO